LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB

BACKGROUND: Targeted therapy aimed at modulating the RAS/RAF/MEK/ERK pathway is of increasing interest for patients with plexiform neurofibromas and low-grade gliomas. Trametinib is an FDA-approved MEK inhibitor that has little published pediatric experience to date. METHODS: A retrospective chart r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Tiffany, McMahon, Kathleen, Hemenway, Molly, Levy, Jean Mulcahy, Foreman, Nicholas, Dorris, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715454/
http://dx.doi.org/10.1093/neuonc/noaa222.409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715454/
http://dx.doi.org/10.1093/neuonc/noaa222.409

Ejemplares similares